Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma
Top Cited Papers
- 15 September 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (18), 3402-3408
- https://doi.org/10.1200/jco.2003.09.140
Abstract
Purpose: To conduct a randomized phase II trial of dose-intense gemcitabine using a standard 30-minute infusion or the fixed dose rate (FDR) infusion (10 mg/m2/min) in patients with pancreatic adenocarcinoma.Keywords
This publication has 14 references indexed in Scilit:
- Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumorsAnnals of Oncology, 1998
- A Phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumorsInvestigational New Drugs, 1997
- GemcitabineDrugs, 1997
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Kinetic Analysis of Human Deoxycytidine Kinase with the True Phosphate Donor Uridine TriphosphateBiochemistry, 1997
- Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabineInvestigational New Drugs, 1996
- Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical eventCancer Chemotherapy and Pharmacology, 1995
- Modulation of deoxycytidylate deaminase in intact human leukemia cells: Action of 2',2'-difluorodeoxycytidineBiochemical Pharmacology, 1992
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991
- Nonparametric Procedures for Selecting the $t$ Population with the Largest $alpha$-QuantilesThe Annals of Mathematical Statistics, 1967